Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Dyslipidemia

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 7 articles:
HTML format
Text format



Single Articles


    September 2015
  1. CAREY EJ, Ali AH, Lindor KD
    Primary biliary cirrhosis.
    Lancet. 2015 Sep 10. pii: S0140-6736(15)00154.
    PubMed     Text format     Abstract available


    March 2015
  2. KASTELEIN JJ, Besseling J, Shah S, Bergeron J, et al
    Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study.
    Lancet. 2015 Mar 2. pii: S0140-6736(14)62115.
    PubMed     Text format     Abstract available


  3. RAAL FJ, Blom DJ
    Anacetrapib in familial hypercholesterolaemia: pros and cons.
    Lancet. 2015 Mar 2. pii: S0140-6736(14)62315.
    PubMed     Text format    


    November 2014
  4. MOHAMMADI D
    The 2014 Prince Mahidol Award winners.
    Lancet. 2014;384:1735.
    PubMed     Text format    


    October 2014
  5. RAAL FJ, Honarpour N, Blom DJ, Hovingh GK, et al
    Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.
    Lancet. 2014 Oct 1. pii: S0140-6736(14)61374.
    PubMed     Text format     Abstract available


  6. RAAL FJ, Stein EA, Dufour R, Turner T, et al
    PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
    Lancet. 2014 Oct 1. pii: S0140-6736(14)61399.
    PubMed     Text format     Abstract available


  7. SANTOS RD, Watts GF
    Familial hypercholesterolaemia: PCSK9 inhibitors are coming.
    Lancet. 2014 Oct 1. pii: S0140-6736(14)61702.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Dyslipidemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: